Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1

References

  1. Podust VN, Brownell JE, Gladysheva TB, Luo RS, Wang C, Coggins MB et al. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci USA 2000; 97: 4579–4584.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. Nawrocki ST, Griffin P, Kelly KR, Carew JS . MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin Investig Drugs 2012; 21: 1563–1573.

    CAS  Article  PubMed  Google Scholar 

  3. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010; 115: 3796–3800.

    CAS  Article  PubMed  Google Scholar 

  4. Nawrocki ST, Kelly KR, Smith PG, Keaton M, Carraway H, Sekeres MA et al. The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine. Clin Cancer Res 2015; 21: 439–447.

    CAS  Article  PubMed  Google Scholar 

  5. Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M et al. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol 2015; 169: 534–543.

    CAS  Article  PubMed  Google Scholar 

  6. Hayashi E, Kuramitsu Y, Okada F, Fujimoto M, Zhang X, Kobayashi M et al. Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics 2005; 5: 1024–1032.

    CAS  Article  PubMed  Google Scholar 

  7. Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA et al. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res 2013; 19: 3577–3590.

    CAS  Article  PubMed  Google Scholar 

  8. Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A . NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010; 70: 10310–10320.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. Liao H, Liu XJ, Blank JL, Bouck DC, Bernard H, Garcia K et al. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924. Mol Cell Proteomics 2011; 10: 009183.

    Article  PubMed  Google Scholar 

  10. Camos M, Esteve J, Jares P, Colomer D, Rozman M, Villamor N et al. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res 2006; 66: 6947–6954.

    CAS  Article  PubMed  Google Scholar 

  11. Mills KI, Kohlmann A, Williams PM, Wieczorek L, Liu WM, Li R et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 2009; 114: 1063–1072.

    CAS  Article  PubMed  Google Scholar 

  12. Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N et al. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell 2015; 27: 658–670.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood 2012; 119: 5229–5238.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Burton TR, Kashour T, Wright JA, Amara FM . Cellular signaling pathways affect the function of ribonucleotide reductase mRNA binding proteins: mRNA stabilization, drug resistance, and malignancy (Review). Int J Oncol 2003; 22: 21–31.

    CAS  PubMed  Google Scholar 

  15. Coude MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget 2015; 6: 17698–17712.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Cancer Institute grant R01CA172443 (to JSC).

Author contributions

VV analyzed and interpreted data and wrote the manuscript; STN analyzed and interpreted data and participated in manuscript preparation; CME performed experiments, analyzed the data, and edited the manuscript; KRK provided intellectual input and contributed to manuscript preparation; AP and SAB performed proteome profiling and contributed to manuscript preparation; YH participated in manuscript preparation; HEC, AN, ASA, JPM and MAS contributed to data interpretation and manuscript preparation; JSC designed the study, analyzed and interpreted data and wrote the manuscript. All authors approved the manuscript before submission.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J S Carew.

Ethics declarations

Competing interests

AP and SAB are employees of Cell Signaling Technology. The other authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Visconte, V., Nawrocki, S., Espitia, C. et al. Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine. Leukemia 30, 1190–1194 (2016). https://doi.org/10.1038/leu.2015.250

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.250

Further reading

Search

Quick links